A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650
at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the
treatment was confirmed after the treatment with Remicade® at 5 mg/kg every 8 weeks but
decreased thereafter.